Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study
BackgroundUrinary 11‐dehydro‐thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients. This part of LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) study aimed to evaluate the relationship bet...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-08-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.116.003702 |
| _version_ | 1819178939166228480 |
|---|---|
| author | Wojciech Szczeklik Edyta Stodółkiewicz Marcin Rzeszutko Marek Tomala Anton Chrustowicz Krzysztof Żmudka Marek Sanak |
| author_facet | Wojciech Szczeklik Edyta Stodółkiewicz Marcin Rzeszutko Marek Tomala Anton Chrustowicz Krzysztof Żmudka Marek Sanak |
| author_sort | Wojciech Szczeklik |
| collection | DOAJ |
| description | BackgroundUrinary 11‐dehydro‐thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients. This part of LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) study aimed to evaluate the relationship between 11‐dehydro‐TXB2 and MACEs in patients with acute myocardial infarction (AMI). Methods and ResultsLTIMI was an observational, prospective study in 180 consecutive patients with AMI type 1 referred for primary percutaneous coronary intervention. On admission and at follow‐up visits (1 month, 1 year), 11‐dehydro‐TXB2 was measured in urinary samples by using high‐performance liquid chromatography–tandem mass spectrometry. The primary outcome was occurrence of composite MACEs during 1‐year after AMI. Left ventricular ejection fraction was assessed in echocardiography on admission and at 1‐year follow‐up. Analyses of 11‐dehydro‐TXB2 (pg/mg creatinine) were performed on log‐transformed data and expressed as median with IQR (Q1–Q3). 11‐Dehydro‐TXB2 level on admission was 7.39 (6.85–8.01) and decreased at 1 month (6.73, 6.27–7.12; P<0.001) and 1‐year follow‐up (6.37, 5.91–6.94; P<0.001). In univariate analysis, baseline 11‐dehydro‐TXB2 was higher in patients with MACEs (n=60; 7.73, 7.07–8.60) compared with those without MACEs (n=119; 7.28, 6.68–7.79; P=0.002). In multivariate regression model, 11‐dehydro‐TXB2 and 3 other variables (diabetes, multivessel disease, and left ventricular ejection fraction) were found to be best 1‐year cumulative MACE predictors with odds ratio for 11‐dehydro‐TXB2 of 1.58 (95% CI 1.095–2.33; P=0.017) and area under the curve (in receiver operating characteristic analysis of 0.8). Baseline 11‐dehydro‐TXB2 negatively correlated with both left ventricular ejection fraction on admission (R=−0.21; P=0.006) and after 1 year (R=−0.346; P<0.001). Conclusions11‐Dehydro‐TXB2 predicts 1‐year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance. |
| first_indexed | 2024-12-22T21:50:31Z |
| format | Article |
| id | doaj.art-f6108a7d7e514bbebca6f47c82a082b4 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-22T21:50:31Z |
| publishDate | 2016-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-f6108a7d7e514bbebca6f47c82a082b42022-12-21T18:11:22ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802016-08-015810.1161/JAHA.116.003702Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) StudyWojciech Szczeklik0Edyta Stodółkiewicz1Marcin Rzeszutko2Marek Tomala3Anton Chrustowicz4Krzysztof Żmudka5Marek Sanak6Department of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Interventional Cardiology, Jagiellonian University Medical College, Krakow, PolandDepartment of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Interventional Cardiology, Jagiellonian University Medical College, Krakow, PolandNoninvasive Cardiovascular Laboratory, John Paul II Hospital, Krakow, PolandDepartment of Interventional Cardiology, Jagiellonian University Medical College, Krakow, PolandDepartment of Medicine, Jagiellonian University Medical College, Krakow, PolandBackgroundUrinary 11‐dehydro‐thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients. This part of LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) study aimed to evaluate the relationship between 11‐dehydro‐TXB2 and MACEs in patients with acute myocardial infarction (AMI). Methods and ResultsLTIMI was an observational, prospective study in 180 consecutive patients with AMI type 1 referred for primary percutaneous coronary intervention. On admission and at follow‐up visits (1 month, 1 year), 11‐dehydro‐TXB2 was measured in urinary samples by using high‐performance liquid chromatography–tandem mass spectrometry. The primary outcome was occurrence of composite MACEs during 1‐year after AMI. Left ventricular ejection fraction was assessed in echocardiography on admission and at 1‐year follow‐up. Analyses of 11‐dehydro‐TXB2 (pg/mg creatinine) were performed on log‐transformed data and expressed as median with IQR (Q1–Q3). 11‐Dehydro‐TXB2 level on admission was 7.39 (6.85–8.01) and decreased at 1 month (6.73, 6.27–7.12; P<0.001) and 1‐year follow‐up (6.37, 5.91–6.94; P<0.001). In univariate analysis, baseline 11‐dehydro‐TXB2 was higher in patients with MACEs (n=60; 7.73, 7.07–8.60) compared with those without MACEs (n=119; 7.28, 6.68–7.79; P=0.002). In multivariate regression model, 11‐dehydro‐TXB2 and 3 other variables (diabetes, multivessel disease, and left ventricular ejection fraction) were found to be best 1‐year cumulative MACE predictors with odds ratio for 11‐dehydro‐TXB2 of 1.58 (95% CI 1.095–2.33; P=0.017) and area under the curve (in receiver operating characteristic analysis of 0.8). Baseline 11‐dehydro‐TXB2 negatively correlated with both left ventricular ejection fraction on admission (R=−0.21; P=0.006) and after 1 year (R=−0.346; P<0.001). Conclusions11‐Dehydro‐TXB2 predicts 1‐year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance.https://www.ahajournals.org/doi/10.1161/JAHA.116.003702atherosclerosiscomplicationinflammationmyocardial infarctionrisk factorthromboxane |
| spellingShingle | Wojciech Szczeklik Edyta Stodółkiewicz Marcin Rzeszutko Marek Tomala Anton Chrustowicz Krzysztof Żmudka Marek Sanak Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease atherosclerosis complication inflammation myocardial infarction risk factor thromboxane |
| title | Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study |
| title_full | Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study |
| title_fullStr | Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study |
| title_full_unstemmed | Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study |
| title_short | Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study |
| title_sort | urinary 11 dehydro thromboxane b2 as a predictor of acute myocardial infarction outcomes results of leukotrienes and thromboxane in myocardial infarction ltimi study |
| topic | atherosclerosis complication inflammation myocardial infarction risk factor thromboxane |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.116.003702 |
| work_keys_str_mv | AT wojciechszczeklik urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT edytastodołkiewicz urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT marcinrzeszutko urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT marektomala urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT antonchrustowicz urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT krzysztofzmudka urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy AT mareksanak urinary11dehydrothromboxaneb2asapredictorofacutemyocardialinfarctionoutcomesresultsofleukotrienesandthromboxaneinmyocardialinfarctionltimistudy |